Drugs / recombinant human GH
recombinant human GH
also known as
Declage Inj. · SR-hGH · SR-rhGH · Sustained-release Human Growth Hormone · sustained-release recombinant human GH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01605331 | Dec 2009 → Sep 2010 | pituitary deficiency | LG Life Sciences | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human GH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01605331 ↗ |
| Known as | Declage Inj. | “Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)” NCT01605331 ↗ |
| Known as | SR-hGH | “Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)” NCT01605331 ↗ |
| Known as | SR-rhGH | “sustained-release recombinant human GH (SR-rhGH)” NCT01605331 ↗ |
| Known as | Sustained-release Human Growth Hormone | “Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)” NCT01605331 ↗ |
| Known as | sustained-release recombinant human GH | “sustained-release recombinant human GH (SR-rhGH)” NCT01605331 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human GH (rhGH)” NCT01605331 ↗ |
| Route | Subcutaneous | “12-week subcutaneous administration, 2mg/week” NCT01605331 ↗ |